Mexico vs Singapore: Statin use vs. average non-HDL cholesterol levels
Mexico
3.8
in 2018
Singapore
3.8
in 2018
Mexico rank
6th
Singapore rank
6th
Statin use vs. average non-HDL cholesterol levels over time
- Mexico
- Singapore
How they compare
Mexico currently reports 3.8 against 3.8 in Singapore, a difference of 0.
The two have swapped places 2 times across 39 shared years of data; in 1980 it was Singapore ahead.
Mexico ranks 6th and Singapore ranks 6th of 191 countries.
Across the 4 decades both report, Mexico averaged higher in 1 and Singapore in 2.
Head to head by decade
| Decade | Mexico | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.9 | 4.53 | 0.63 | Singapore |
| 1990s | 3.9 | 3.94 | 0.04 | Singapore |
| 2000s | 3.89 | 3.8 | 0.09 | Mexico |
| 2010s | 3.8 | 3.8 | 0 | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Mexico or Singapore?
- Mexico, at 3.8 against 3.8 in Singapore as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Mexico and Singapore?
- 0, with Mexico ahead.
- How many years of comparable data are there for Mexico and Singapore?
- 39 years are reported by both, from 1980 to 2018.
- How do Mexico and Singapore rank globally for statin use vs. average non-hdl cholesterol levels?
- Mexico ranks 6th and Singapore ranks 6th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.